Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy

We aim to determine the feasibility of a novel radiomic biomarker that can integrate with other established clinical prognostic factors to predict progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) undergoing first-line immunotherapy. Our study includes 107 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Apurva, Horng, Hannah, Roshkovan, Leonid, Weeks, Joanna K., Hershman, Michelle, Noël, Peter, Luna, José Marcio, Cohen, Eric A., Pantalone, Lauren, Shinohara, Russell T., Bauml, Joshua M., Thompson, Jeffrey C., Aggarwal, Charu, Carpenter, Erica L., Katz, Sharyn I., Kontos, Despina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200843/
https://www.ncbi.nlm.nih.gov/pubmed/35705618
http://dx.doi.org/10.1038/s41598-022-14160-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200843/
https://www.ncbi.nlm.nih.gov/pubmed/35705618
http://dx.doi.org/10.1038/s41598-022-14160-7

Ejemplares similares